NYU LANGONE HEALTH

Researchers at NYU Langone Health developed a bispecific antibody called BiTS that targets both T cell receptors and LAG-3 checkpoints to selectively suppress autoimmune T cells.

Researchers analyzed genetic material from 1,225 metastatic melanoma patients and identified that those with mitochondrial haplogroup T (HG-T) were 3.46 times less likely to respond to checkpoint inhibitor therapy.

URO-1's SUREcore biopsy needle demonstrated 92% targeting accuracy compared to 36% for standard needles, representing a major advancement in prostate cancer diagnostics.

Circulating tumor DNA (ctDNA) monitoring can reliably identify minimal residual disease in patients with resected stage III melanoma, predicting high risk of early recurrence even when patients appear disease-free by radiographic measures.

A new Ultra-Rapid droplet digital PCR test can detect brain cancer cells in tissue samples within 15 minutes, providing surgeons with real-time feedback during operations.

NYU Langone researchers have discovered that BRCA2 acts as a molecular shield preventing PARP1 from binding to DNA damage sites, explaining why PARP inhibitors are effective only in certain cancer patients.

Nutrition plays a vital role throughout the cancer journey, with different dietary strategies needed during active treatment versus survivorship and prevention phases.

A landmark study by NYU Langone Health reveals kidney transplant recipients with type 2 diabetes who take GLP-1 agonists experience 49% lower risk of organ failure and 31% reduced mortality within five years.

Francis Medical has successfully completed enrollment of 235 patients across 26 US sites in the pivotal VAPOR 2 trial, evaluating the Vanquish Water Vapor Ablation device for intermediate-risk prostate cancer.

Healthcare experts highlight the integration of AI screening technology with community health workers as a promising solution to improve clinical trial access and patient identification efficiency.